Parameter
| Biomarker | PR | Full name | Progesterone receptor | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, prognosis |
| Disease | Breast Cancer | Disease Subtypes | / | ||
| Organ | Breast | Test Sample / Technology Platform | Tumor tissue (IHC, IF) | ||
| Pathobiological Mechanisms | The expression of PR is regulated by ER. Its presence indicates that the ER signaling pathway is intact and can enhance the sensitivity to endocrine therapy. | ||||
| Clinical Availability Status | Clinical routine (recommended by guidelines): When combined with ER testing, PR-positive patients have a clearer benefit from endocrine therapy. | ||||
| Notes and Dynamics | Some patients experienced PR loss during the treatment process, which was related to endocrine resistance. Dynamic monitoring is necessary. | ||||